Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$130.93
+0.7%		$118.46
$67.15
▼
$148.83
$11.34B1.03991,257 shs1.09 million shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$63.81
+3.8%		$58.19
$49.26
▼
$66.28
$11.88B0.241.71 million shs4.37 million shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$69.48
+9.6%		$66.71
$29.95
▼
$118.84
$2.72B3.24552,613 shs1.64 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$510.04
-0.1%		$515.31
$339.31
▼
$615.00
$11.79B-1.01379,964 shs347,529 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
+3.68%+4.56%-8.56%+5.91%+88.16%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
+2.59%+1.45%+1.84%+13.69%+1.30%
GRAIL, Inc. stock logo
GRAL
GRAIL
-14.53%-10.88%-7.84%+2.86%+91.66%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-0.73%+3.50%-6.42%+0.06%+50.94%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$130.93
+0.7%		$118.46
$67.15
▼
$148.83
$11.34B1.03991,257 shs1.09 million shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$63.81
+3.8%		$58.19
$49.26
▼
$66.28
$11.88B0.241.71 million shs4.37 million shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$69.48
+9.6%		$66.71
$29.95
▼
$118.84
$2.72B3.24552,613 shs1.64 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$510.04
-0.1%		$515.31
$339.31
▼
$615.00
$11.79B-1.01379,964 shs347,529 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
+3.68%+4.56%-8.56%+5.91%+88.16%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
+2.59%+1.45%+1.84%+13.69%+1.30%
GRAIL, Inc. stock logo
GRAL
GRAIL
-14.53%-10.88%-7.84%+2.86%+91.66%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-0.73%+3.50%-6.42%+0.06%+50.94%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2.80
Moderate Buy$156.5019.53% Upside
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.71
Moderate Buy$87.8637.70% Upside
GRAIL, Inc. stock logo
GRAL
GRAIL
2.30
Hold$67.78-2.45% Downside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.78
Moderate Buy$689.9335.27% Upside

Current Analyst Ratings Breakdown

Latest GRAL, BMRN, ABVX, and MDGL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/7/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$95.00 ➝ $97.00
8/7/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$119.00 ➝ $124.00
8/7/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$50.00 ➝ $60.00
8/4/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$605.00
8/3/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$964.00 ➝ $962.00
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$964.00 ➝ $962.00
7/29/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$578.00 ➝ $587.00
7/27/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$685.00
7/27/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$685.00
(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/A$6.57 per shareN/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$3.22B3.83$2.96 per share21.54$31.68 per share2.01
GRAIL, Inc. stock logo
GRAL
GRAIL
$147.17M20.26N/AN/A$66.13 per share1.05
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M12.29N/AN/A$22.67 per share22.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%9/21/2026 (Estimated)
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$348.90M$1.37172.4611.330.472.14%5.36%4.13%10/26/2026 (Estimated)
GRAIL, Inc. stock logo
GRAL
GRAIL
-$408.35M-$10.37N/AN/AN/A-236.95%-16.05%-14.11%N/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A91.90N/A-25.32%-56.65%-25.53%N/A

Latest GRAL, BMRN, ABVX, and MDGL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$0.95$1.20+$0.25$0.23$932.03 million$989.71 million
8/5/2026Q2 2026
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.66-$2.56+$0.10-$2.56$42.39 million$44.69 million
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
5/22/2026Q1 2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/AN/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
8.25
8.25
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.23
5.81
4.20
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
11.74
11.74
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94

Institutional Ownership

CompanyInstitutional Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
47.91%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%

Insider Ownership

CompanyInsider Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.68%
GRAIL, Inc. stock logo
GRAL
GRAIL
1.83%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6187.25 millionN/ANot Optionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,221193.28 million191.97 millionOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
1,36042.92 million42.13 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9023.10 million19.04 millionOptionable

Recent News About These Companies

Madrigal Pharmaceuticals (NASDAQ:MDGL) Raised to Outperform at Wolfe Research
August 6 at 3:00 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30943788
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Recommendation of "Moderate Buy" by Analysts
August 6 at 2:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30943610
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of "Moderate Buy" from Analysts
August 6 at 2:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/madrigal-pharmaceuticals-inc-nasdaqmdgl-receives-average-rating-of-moderate-buy-from-analysts-2026-08-06/
HC Wainwright Analysts Lift Earnings Estimates for MDGL
August 6 at 1:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30943179
Madrigal Pharmaceuticals: Semaglutide Launch No Issue, Wise Pipeline Approach
August 5 at 3:56 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4930531-madrigal-pharmaceuticals-semaglutide-launch-no-issue-wise-pipeline-approach
California State Teachers Retirement System Buys 3,039 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
August 5 at 3:36 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-buys-3039-shares-of-madrigal-pharmaceuticals-inc-mdgl-2026-08-05/
HC Wainwright Analysts Increase Earnings Estimates for MDGL
August 4 at 8:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-analysts-increase-earnings-estimates-for-mdgl-2026-08-04/
Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded to Outperform at Wolfe Research
August 4 at 8:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/madrigal-pharmaceuticals-nasdaqmdgl-upgraded-to-outperform-at-wolfe-research-2026-08-04/
Madrigal Pharmaceuticals (MDGL) Gets a Buy from Truist Financial
August 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MDGL/pressreleases/3593345/madrigal-pharmaceuticals-mdgl-gets-a-buy-from-truist-financial/
Principal Financial Group Inc. Sells 6,022 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-principal-financial-group-inc-sells-6022-shares-of-madrigal-pharmaceuticals-inc-mdgl-2026-08-01/
Groupama Asset Managment Buys 4,618 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-groupama-asset-managment-buys-4618-shares-of-madrigal-pharmaceuticals-inc-mdgl-2026-08-01/
Canaccord Genuity Remains a Buy on Madrigal Pharmaceuticals (MDGL)
July 31, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MDGL-Q/pressreleases/3547851/canaccord-genuity-remains-a-buy-on-madrigal-pharmaceuticals-mdgl/
Madrigal: I Can't Bet Against A Company Performing This Well (Upgrade)
July 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4928689-madrigal-i-cant-bet-against-a-company-performing-this-well-upgrade
Madrigal Pharmaceuticals (NASDAQ:MDGL) Issues Earnings Results, Beats Expectations By $0.69 EPS
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/madrigal-pharmaceuticals-nasdaqmdgl-issues-earnings-results-beats-expectations-by-069-eps-2026-07-30/
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth
July 31, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2965895/mdgl-stock-down-despite-q2-beat-mash-drug-drives-top-line-y-y-growth?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2965895
First Trust Advisors LP Sells 2,586 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-first-trust-advisors-lp-sells-2586-shares-of-madrigal-pharmaceuticals-inc-mdgl-2026-07-31/
Madrigal: Q2 Earnings Snapshot
July 30, 2026  |  chron.comhttps://www.chron.com/business/article/madrigal-q2-earnings-snapshot-22366753.php
Madrigal Pharmaceuticals (MDGL) Q2 2026 Earnings
July 30, 2026  |  247wallst.comhttps://247wallst.com/cards/madrigal-pharmaceuticals-q2-2026-earnings-mdgl-01kysbgnmp9gw60dv52g1a4pa5
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Short Interest Update
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/madrigal-pharmaceuticals-inc-nasdaqmdgl-short-interest-update-2026-07-30/
Madrigal Pharmaceuticals Q2 Earnings Call Highlights
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/madrigal-pharmaceuticals-q2-earnings-call-highlights-2026-07-30/
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2026 Earnings Call Transcript
July 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4927737-madrigal-pharmaceuticals-inc-mdgl-q2-2026-earnings-call-transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abivax stock logo

Abivax NASDAQ:ABVX

$130.93 +0.93 (+0.72%)
Closing price 04:00 PM Eastern
Extended Trading
$131.09 +0.16 (+0.12%)
As of 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$63.81 +2.35 (+3.82%)
Closing price 04:00 PM Eastern
Extended Trading
$62.50 -1.31 (-2.05%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

GRAIL stock logo

GRAIL NASDAQ:GRAL

$69.48 +6.08 (+9.59%)
Closing price 04:00 PM Eastern
Extended Trading
$69.12 -0.36 (-0.52%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$510.04 -0.32 (-0.06%)
Closing price 04:00 PM Eastern
Extended Trading
$504.00 -6.04 (-1.18%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas